| P50 | author | Hisashi Yamanaka | Q88712489 |
| | Dhananjay Bakhle | Q91944389 |
| P2093 | author name string | Chirag Shah | |
| | Toshihiko Hibino | |
| | Yoshiya Tanaka | |
| | Naoyuki Kamatani | |
| | Juan Sánchez-Bursón | |
| | Edit Drescher | |
| | Girish Bhatia | |
| | Manfred Rettenbacher | |
| | Snehal Gadve | |
| P2860 | cites work | Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? | Q26744032 |
| | The changing landscape of biosimilars in rheumatology | Q26766515 |
| | A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate | Q28295474 |
| | Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry | Q30940329 |
| | Allergy to latex | Q35175594 |
| | Clinical pharmacokinetics of TNF antagonists: how do they differ? | Q36106353 |
| | Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins | Q36188312 |
| | Effects of protein aggregates: an immunologic perspective | Q36616319 |
| | A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy | Q37604518 |
| | Impact of product-related factors on immunogenicity of biotherapeutics | Q37782596 |
| | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | Q40305889 |
| | Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis | Q44003346 |
| | Treatment with Biologicals in Rheumatoid Arthritis: An Overview. | Q47132835 |
| | American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 |
| | Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA | Q59329010 |
| | Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses | Q64075128 |
| | A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis | Q73235899 |
| | Development of anti-TNF therapy for rheumatoid arthritis | Q74187188 |
| | Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes | Q74455180 |
| P433 | issue | 1 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P1104 | number of pages | 15 | |
| P304 | page(s) | 149-163 | |
| P577 | publication date | 2019-12-12 | |
| P1433 | published in | Rheumatology and therapy | Q27727370 |
| P1476 | title | A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis | |
| P478 | volume | 7 | |